ScholarIQanswers from OpenAlex & ORCID
David S. Shames
ResearcherPublications, citations & collaboration network
David S. Shames is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David S. Shames have?
ScholarIQindexed works
David S. Shames has 330 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David S. Shames have?
ScholarIQcitation count
David S. Shames has 20,009 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David S. Shames?
ScholarIQh-index
David S. Shames has an h-index of 65 in OpenAlex.
What is the i10-index of David S. Shames?
ScholarIQi10-index
David S. Shames has an i10-index of 108 in OpenAlex.
What is the ORCID of David S. Shames?
ScholarIQorcid
The ORCID for David S. Shames is on the source record.
What is the OpenAlex record for David S. Shames?
ScholarIQopenalex
The OpenAlex for David S. Shames is on the source record.
What are the most-cited papers on David S. Shames?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin, Steffen Durinck, Eric Stawiski, John T. Poirier, Zora Modrušan, David S. Shames, Emily Anne Smith Bergbower, Yinghui Guan, James Shin, Joseph Guillory, Celina Sanchez Rivers, Catherine K. Foo, Deepali Bhatt, Jeremy Stinson, Florian Gnad, Peter M. Haverty, Robert Gentleman, Subhra Chaudhuri, Vasantharajan Janakiraman, Bijay S. Jaiswal, Chaitali Parikh, Wenlin Yuan, Zemin Zhang, Hartmut Koeppen, Thomas D. Wu, Howard M. Stern, Robert L. Yauch, Kenneth E. Huffman, Diego D’Ávila Paskulin, Peter B. Illei, Marileila Varella‐Garcia, Adi F. Gazdar, Frédéric J. de Sauvage, Richard Bourgon, John D. Minna, Malcolm V. Brock, Somasekar Seshagiri
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok